Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Abeona Therapeutics Inc. (ABEO : NSDQ)

• Company Description    Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $5.27 Daily Weekly Monthly 20 Day Moving Average: 1,043,673 shares Shares Outstanding: 54.19 (millions) Market Capitalization: $285.59 (millions) Beta: 1.12 52 Week High: $7.54 52 Week Low: $3.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.21% 8.40% 12 Week -6.89% -8.39% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6555 Carnegie Avenue 4thFloor - Cleveland,OH 44103 USA ph: 646-813-4701 fax: 214-905-5101 ir@abeonatherapeutics.com http://www.abeonatherapeutics.com

• General Corporate Information    Officers Vishwas Seshadri - Chief Executive Officer; President and Director Michael Amoroso - Chairman of the Board and Director Joseph Vazzano - Chief Financial Officer Leila Alland - Director Mark J. Alvino - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00289Y206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 54.19 Most Recent Split Date: 7.00 (0.04:1) Beta: 1.12 Market Capitalization: $285.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: 4.06 Trailing 12 Months: 4.66 PEG Ratio: - Price Ratios Price/Book: 1.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 67.74% vs. Previous Quarter: -105.85% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - 71.94 06/30/25 - 89.05 ROA 12/31/25 - - 09/30/25 - 44.09 06/30/25 - 45.64 Current Ratio 12/31/25 - - 09/30/25 - 9.74 06/30/25 - 6.73 Quick Ratio 12/31/25 - - 09/30/25 - 9.53 06/30/25 - 6.65 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - 20,666.25 06/30/25 - 18,188.50 Book Value 12/31/25 - - 09/30/25 - 3.34 06/30/25 - 3.20 Inventory Turnover 12/31/25 - - 09/30/25 - 0.26 06/30/25 - 0.00 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.06 06/30/25 - 0.09 Debt-to-Capital 12/31/25 - - 09/30/25 - 5.97 06/30/25 - 7.89

Powered by Zacks Investment Research ©